Streetbeat News

TARO

Taro Pharmaceutical Industries

http://www.taro.com

CEO

Uday Baldota

Employees

1,339

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

established in 1950, taro pharmaceutical industries ltd. is a research-based, international, specialty pharmaceutical company that develops, manufactures and markets prescription and over-the-counter pharmaceutical products. taro’s research programs and niche strategy have enabled the company to achieve gross margins that are among the highest in the specialty pharmaceutical sector.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Taro Pharmaceutical Industries Ltd. and certain officers, offering shareholders the opportunity to lead the lawsuit.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Sun Pharmaceutical and Taro Pharmaceutical Industries' merger agreement has been approved by the affirmative vote of Taro shareholders.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2024 | 11:56 am

Taro Pharmaceutical Industries (NYSE:TARO) reported Q4 adjusted EPS of $0.43, beating the estimate of $0.31 by 38.71%. Sales were $164.941M, surpassing the $156.062M estimate and marking a 12.52% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 9:16 pm

Krensavage Asset Management, the largest minority shareholder of Taro Pharmaceutical Industries Ltd. (NYSE:TARO), has expressed opposition to Sun Pharmaceutical Industries Ltd.'s bid to acquire Taro. Krensavage deems the offer inadequate and has communicated this stance to the special committee evaluating the bid.

Portfolio Pulse from Benzinga Newsdesk

January 30, 2024 | 12:07 pm

Taro Pharmaceutical Industries (NYSE:TARO) reported Q3 2024 earnings of $0.54 per share, surpassing the consensus estimate of $0.30 by 80%. Quarterly sales were $157.10 million, exceeding estimates by 1.42% and marking a 12.86% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 10:07 pm

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) reported Q3 sales of $157.10M, surpassing the consensus estimate of $154.91M by 1.42% and marking a 12.86% increase from $139.20M in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 10:07 pm

Taro Pharmaceutical Indus (NYSE:TARO) is scheduled to release its quarterly earnings report on Thursday, 2024-01-25, with analysts expecting an EPS of $0.30. Investors are looking for an earnings beat and positive guidance for future growth. Historically, TARO's stock price has shown varied reactions to past earnings performances, with a 2.3% drop after beating EPS last quarter. Shares are currently trading at $42.07, up 37.71% over the last 52 weeks, indicating a bullish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

January 24, 2024 | 7:01 pm

HC Wainwright & Co. analyst Raghuram Selvaraju has downgraded Taro Pharmaceutical Industries (NYSE:TARO) from Buy to Neutral while maintaining the price target at $43.

Portfolio Pulse from Benzinga Newsdesk

January 18, 2024 | 11:15 am

Taro Pharmaceutical has entered into a definitive merger agreement with Sun Pharma, where Sun Pharma will acquire all outstanding ordinary shares of Taro for $43 per share. This acquisition price represents a 48% premium over the unaffected share price on May 25, 2023.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 9:32 pm

Taro Pharmaceutical Indus (NYSE:TARO) reported Q2 2023 earnings of $0.38 per share, beating the analyst consensus estimate of $0.18 by 111.11%. However, this is a 42.42% decrease from the same period last year. The company's quarterly sales of $148.20 million missed the analyst consensus estimate of $161.14 million by 8.03%, but it's a 13.57% increase from the same period last year.

Portfolio Pulse from saritha@benzinga.com

October 26, 2023 | 9:11 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.